286 related articles for article (PubMed ID: 32719307)
1. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
[TBL] [Abstract][Full Text] [Related]
3. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
[TBL] [Abstract][Full Text] [Related]
6. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.
Giral M; Grimbert P; Morin B; Bouvier N; Buchler M; Dantal J; Garrigue V; Bertrand D; Kamar N; Malvezzi P; Moreau K; Athea Y; Le Meur Y
Transpl Int; 2024; 37():11571. PubMed ID: 38694490
[TBL] [Abstract][Full Text] [Related]
7. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
8. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
Transpl Int; 2022; 35():10225. PubMed ID: 36017158
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients.
Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC
J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556
[No Abstract] [Full Text] [Related]
10. Extended-release tacrolimus dosing and outcomes in pediatric and young adult transplant recipients - A single-center experience.
Huang X; Hapgood K; Allan K; Pruette C; Goswami E
Pediatr Transplant; 2024 Feb; 28(1):e14611. PubMed ID: 37735900
[TBL] [Abstract][Full Text] [Related]
11. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
[TBL] [Abstract][Full Text] [Related]
12. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study.
Bilbao I; Gómez Bravo MÁ; Otero A; Lladó L; Montero JL; González Dieguez L; Graus J; Pons Miñano JA
Clin Transplant; 2023 Dec; 37(12):e15105. PubMed ID: 37615653
[TBL] [Abstract][Full Text] [Related]
15. De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial.
van Zyl JS; Sam T; Clark DM; Felius J; Doss AK; Kerlee KR; Cheung ZO; Martits-Chalangari K; Jamil AK; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA
Clin Transplant; 2021 Dec; 35(12):e14487. PubMed ID: 34529289
[TBL] [Abstract][Full Text] [Related]
16. Early outcomes associated with de novo once-daily extended-release versus twice-daily immediate-release tacrolimus in a predominantly African American kidney transplant population: A single-center observational study.
Romine MM; Leeser DB; Kennamer K; Nguyen C; Jones H; McLawhorn K; Kendrick S; Irish W
Clin Transplant; 2024 Mar; 38(3):e15268. PubMed ID: 38450751
[TBL] [Abstract][Full Text] [Related]
17. The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients.
Torabi J; Konicki A; Rocca JP; Ajaimy M; Campbell A; Azzi Y; Pynadath C; Liriano-Ward L; Akalin E; Kinkhabwala M; Graham JA
Am J Surg; 2020 Apr; 219(4):583-586. PubMed ID: 32122660
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
19. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; Calvo Rodríguez M; Poveda JL; Pascual J; Crespo M; Gomez G; Cabello Pelegrin S; Paul J; Lauzurica R; Perez Mir M; Moreso F; Perelló M; Andres A; González E; Fernandez A; Mendiluce A; Fernández Carbajo B; Sanchez Fructuoso A; Calvo N; Suarez A; Bernal Blanco G; Osuna A; Ruiz-Fuentes MC; Melilli E; Montero Perez N; Ramos A; Fernández B; López V; Hernandez D;
Clin Transplant; 2022 Mar; 36(3):e14550. PubMed ID: 34851532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
